Navigation Links
EntreMed Initiates Plans for China Office
Date:3/5/2012

a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking Statements         

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of f
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BioPharma Inc. (NASDAQ: ARRY ) today reported ... year ending June 30, 2015. Ron ... close of the Novartis-GSK transaction, Array now owns ... in Phase 3, with plans for regulatory submissions ... have accelerated our path to commercialization and provide ...
(Date:5/3/2015)... , May 4, 2015 A new ... and families to reduce asthma-related illness. ... that pharmacies in neighborhoods with high rates of ... controller medications compared to asthma rescue medications. ... living in poverty or with limited access to ...
(Date:5/1/2015)... 1, 2015 Hitachi Chemical Diagnostics, Inc. is ... launch of the ExoComplete™ 96-Well Plate Kit and ... for exosome collection to mRNA purification.  The products were ... Annual Meeting, April 23 – 26, 2015, in ... for research use only of molecular biology applications and ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10New Study Suggests Prominent Role for Pharmacies In Reducing Asthma-related Illness 2New Study Suggests Prominent Role for Pharmacies In Reducing Asthma-related Illness 3New Products for Exosome Isolation to mRNA Purification 2
... NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical ... announced that it has entered into a $20 million ... HTGC).  The loan agreement includes both a $5 million ... term loan. Proceeds are expected to be ...
... Aug. 8, 2011 Global Health Ventures Inc. ... on sublingual drug delivery announced today that their August ... and CEO, is available for on-demand viewing. ... watch event now" button. Their presentation will ...
Cached Medicine Technology:NeurogesX, Inc. Secures $20 Million Debt Facility 2NeurogesX, Inc. Secures $20 Million Debt Facility 3NeurogesX, Inc. Secures $20 Million Debt Facility 4Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:5/4/2015)... “ Food Cost Calculator ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... manage and efficiently calculate food costs. , The restaurant industry ... the industry has an estimated 1.8 trillion dollar impact on ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
(Date:5/4/2015)... “St. Louis has long represented opportunity and ... so it is the perfect place for Zerorez to ... Litalien, Chief Development Officer for Zerorez. “We have ... provide veterans with a $10,000 discount on our franchise ... a number of Military Veterans in its ranks including ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 03, 2015 ... . She has worked to enhance the well being of ... as a generalist in a hospital, followed by providing care for ... I worked with as an Adult Nurse Practitioner began wondering if ... coupled with the birth of my own children with my mentor ...
Breaking Medicine News(10 mins):Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2
... thirty poor women of the fishing community, living on Chennai’s ... The 1994 Transplant of Human Organ Act ... to donate kidneys for transplantation. However a recent report from ... that several leading hospitals in the state encouraged the economically ...
... 50% of sexually active gay men in the UK had unprotected ... the 2005 Gay Men’s Sex Survey//, Consuming Passions, which has been ... of gay men in the UK are unaware of their own ... not disclosed their HIV infection status. ,The study ...
... on 4,000 pregnant women one-fifth of them had to undergo ... failed//. Researchers found that obesity impairs the ability of the ... and deliver the baby. ,In a study of ... overweight women had to undergo an emergency Caesarean Section birth ...
... the Virginia Tech sure had the whole world reaching out ... //An incident unbelievable, the shooting had aftermaths throughout the world. ... family of the people who died at the university. ... to come to term with the whole incident. It will ...
... fetuses could survive. And they have, one in thirty. Such ... hospitals. // ,Most of these babies with ... and all lived for no more than a few hours, ... Obstetrics and Gynaecology study. ,About 190,000 abortions take ...
... one is aware that strawberries are good for health. ... form makes it healthier. // ,While exploring ... from Thailand and the US discovered that treating the ... capacity and free radical scavenging activity within the fruit. ...
Cached Medicine News:Health News:Kidney Trade: Curbing the Sale 2Health News:Kidney Trade: Curbing the Sale 3Health News:One-fifth of Obese Women Undergo Caesarean Due to Uterus Failure 2Health News:Support for Trauma and Grief 2Health News:Aborted Babies Survive, a British Study Says 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: